Outlook Therapeutics, Inc.

OTLK

US69012T3059

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 09/05/2024 BST			5-day change	1st Jan Change
7.73 ^USD	-3.38%		-9.06%	-1.90%

04-15	Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	CI
04-15	Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	CI

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

April 14, 2024

On April 15, 2024, Outlook Therapeutics, Inc. closed the transaction. The warrants have an exercise price of $7.70 per share of common stock and will expire on April 15, 2029.

Latest news about Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	04-14	CI
Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	04-14	CI
North American Morning Briefing : Stocks Set for -2-	03-28	DJ
Outlook Therapeutics Shares Rise After BTIG Upgrade	03-27	MT
BTIG Upgrades Outlook Therapeutics to Buy From Neutral, Price Target at $50	03-27	MT
Outlook Therapeutics Reports Secondary Share Offering	03-25	MT
Sector Update: Health Care Stocks Ease Late Afternoon	03-22	MT
Sector Update: Health Care Stocks Ease Friday Afternoon	03-22	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	03-22	MT
Outlook Therapeutics Gets EMA Panel Positive Opinion for Wet AMD Treatment -- Shares Rise Pre-Bell	03-22	MT
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	03-22	CI
Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors	03-17	CI
Outlook Therapeutics to Begin Reverse Stock Split for Regaining Nasdaq Compliance	03-12	MT
North American Morning Briefing : S&P 500 Seen -2-	02-16	DJ
Outlook Therapeutics Shares Climb Following Upgrade by Chardan	02-15	MT
Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target; Says Risk/Reward is Favorable for Lytenava BLA Resubmission	02-15	MT
Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target	02-15	MT
Outlook Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-14	CI
North American Morning Briefing :Stock Futures -2-	02-14	DJ
Outlook Therapeutics Doses First Patient in Eye Disease Study	01-31	MT
Outlook Therapeutics, Inc. Doses First Subject in Norse Eight	01-31	CI
North American Morning Briefing : Intel Drags Down -2-	01-26	DJ
Guggenheim Upgrades Outlook Therapeutics to Buy From Neutral, Sets Price Target at $2	01-25	MT
Brookline Capital Upgrades Outlook Therapeutics to Buy From Hold, Price Target is $1.57	01-25	MT
Sector Update: Health Care Stocks Decline Late Afternoon	01-23	MT

Chart Outlook Therapeutics, Inc.

Duration

Period

More charts

Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.

Sector

Biotechnology & Medical Research

Calendar

14/05/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8 USD

Average target price

39.86 USD

Spread / Average Target

+398.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OUTLOOK THERAPEUTICS, INC.	-1.90%	186M
MODERNA, INC.	+23.37%	46.71B
LONZA GROUP AG	+48.83%	41.8B
IQVIA HOLDINGS INC.	-0.94%	41.52B
CELLTRION, INC.	-5.86%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.29%	25.78B
ALNYLAM PHARMACEUTICALS, INC.	-20.92%	19.26B
BIO-TECHNE CORPORATION	+3.20%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	12.08B
MEDPACE HOLDINGS, INC.	+30.23%	11.98B

Other Biotechnology & Medical Research